title: Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage.
abstract: The purpose of this study was to retrospectively review outcomes in patients undergoing pancreas transplantation (PTX) with a novel induction protocol of alternate-day thymoglobulin (rATG) in combination with tacrolimus (TAC), mycophenolate mofetil (MMF), and steroids. From January 2002 through January 2005, we performed 55 PTXs in 53 patients. The first dose of rATG (1.5 mg/kg) was given intraoperatively, and subsequent doses were given on alternate days until therapeutic TAC levels (>8 ng/mL) were achieved. All patients underwent PTX with enteric drainage, including 51 with portal and 4 with systemic venous drainage. Patients received a minimum of 2 and maximum of 6 doses of rATG induction (median 3 doses). The patient group had a mean age of 42.8 years and included 40 simultaneous kidney-PTX, 11 sequential PTX after kidney, and 4 PTX-alone transplant recipients. Patient, kidney, and pancreas graft survival rates are 96%, 96%, and 84%, respectively, with a mean follow-up of 21 months. The incidence of acute rejection was 18%; there were no graft losses due to isolated acute rejection. The incidence of infection was 60%, but there were no cases of polyomavirus or Epstein-Barr virus infection and only 6 cases (11%) of cytomegalovirus infection. The composite endpoint of no rejection, graft loss, or mortality was attained by 71% of patients. At present, 94% of surviving patients are both dialysis and insulin-free, including 5 successful PTX retransplants. These findings suggest that PTX with portal-enteric drainage and alternate day rATG induction may result in excellent intermediate-term outcomes.
authors.affiliation: Dept. of General Surgery, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157-1095, USA. rstratta@wfubmc.edu
authors.forename: R J
authors.initials: RJ
authors.lastname: Stratta
authors.forename: A K
authors.initials: AK
authors.lastname: Sundberg
authors.forename: A C
authors.initials: AC
authors.lastname: Farney
authors.forename: M S
authors.initials: MS
authors.lastname: Rohr
authors.forename: E L
authors.initials: EL
authors.lastname: Hartmann
authors.forename: P L
authors.initials: PL
authors.lastname: Adams
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D004322:Drainage; D004334:Drug Administration Schedule; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology* / Q000379:methods* / Q000401:mortality; D011168:Portal System; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents